GlassScriptPhysician profile
Matthew Alan Colna
NPI 1558713560
$6,234.04
in general payments reported to CMS, 2019-2025
21 companies · $3,578 in 2025
The $3,578 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $81.70 · 2021: $881 · 2022: $769 · 2023: $542 · 2024: $381 · 2025: $3,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,830 · Travel and Lodging: $667 · Education: $5.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,829.71 |
| Travel and Lodging | $667.24 |
| Education | $5.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $1,369.71 | 2023-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $903.27 | 2020-2024 | Lifevest |
| Abiomed | $772.68 | 2025 | |
| Abbott Laboratories | $673.14 | 2021-2025 | Cardiomems, Gallant, Thoratec Heartmate 3 Lvas Implant Kit |
| E.R. Squibb & Sons, L.L.C. | $596.64 | 2024-2025 | Camzyos, Eliquis, Cobenfy |
| Astrazeneca Pharmaceuticals LP | $295.97 | 2021-2025 | Wainua, Brilinta, Farxiga |
| Novartis Pharmaceuticals Corporation | $290.31 | 2021-2024 | |
| Pfizer INC. | $269.31 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $220.04 | 2025 | |
| Medtronic, INC. | $193.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $139.11 | 2021-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $113.41 | 2022-2025 | Amvuttra |
| Actelion Pharmaceuticals US, INC. | $66.22 | 2022-2023 | Uptravi, Opsumit |
| Boston Scientific Corporation | $58.56 | 2025 | General - Tachy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.44 | 2022-2024 | Jardiance |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elutia, INC. | $45.49 | 2022 | |
| Merck Sharp & Dohme LLC | $42.98 | 2024-2025 | Verquvo |
| Daiichi Sankyo INC. | $41.31 | 2022-2023 | Injectafer |
| Zoll Respicardia, INC. | $33.49 | 2023 | Remede System |
| Lantheus Medical Imaging, INC. | $32.62 | 2023 | Definity |
| United Therapeutics Corporation | $25.51 | 2025 | Tyvaso |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Colna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.